Revive Therapeutics Ltd. C.RVV

RVV / RVVTF Finacial Statements Months Ended March 31,2020

[TECHNICALGURU]

RVV / RVVTF Finacial Statements Three and Nine Months Ended March 31,2020
( Epressed in Canadian Dollars )

https://backend.otcmarkets.com/otcapi/company/financial-report/257054/content

So it would make sence that the news comimg out will be regarding another Brokered Private Placement and to be conservitive for Execution And Follow Through Of Phase 3. Plus costs to bring it to market if Phase 3 is successful.

Sept or Oct 2020 Brokered Private Placement
Shares    50,000,000 @ .15 =   $7,500,000.00
Warrents 50,000,000 @ .20 = $10,000,000.00

Total Proceeds = $17,500,000.00

MARCH 18, 2020

70,088,150 Shares / Warrents = $4,205,289.00

APRIL 15, 2020

34,279.000 Shares / Warrents = $2,056,560.00

That is a Total of 104,364,150 Shares / Warrents Total Proceeds $6,261,849.00

 

Below Table 1: Respritory System  Phase 3 costs 23.1 $Million 
                                                            Phase 4 costs 72.9 $Million 

The cost of clinical trials vary based on therapeutic area. The average cost of clinical trials across all therapeutic areas in the US was around $30-40 million before approval (Phase 1+2+3) and roughly equivalent amount post approval (Phase 4). The total cost increases by few million dollars every year.

Here's a complete breakdown of costs as reported in 2014 by the US Department of Health and Human Services: https://aspe.hhs.gov/sp/reports/2014/ClinicalTrials/rpt_erg.pdf
 

The model uses detailed cost information made available by Medidata Solutions, a global provider of cloud-based solutions for clinical research in life sciences. The cost information is specific to the U.S. and presented by therapeutic area and clinical trial phase. Key findings with respect to costs include the following:

 

• Overall, the therapeutic area with the highest average per-study costs across Phases 1, 2 and 3 is pain and anesthesia ($71.3 million) followed by ophthalmology ($49.9 million) and antiinfective ($41.3 million) trials. Conversely, trials in dermatology, endocrinology, and gastroenterology have the lowest overall costs across the same three phases.
• Average per-study costs across all therapeutic areas increase as clinical development proceeds from Phase 1 to Phases 2 and 3. Average Phase 4 study costs are equivalent to those of Phase 3 costs but are much more variable across different therapeutic areas than Phase 3 costs.
• Overall, the factors that contribute the most to costs across all trial phases include Clinical Procedure Costs (15 to 22 percent), Administrative Staff Costs (11 to 29 percent), Site Monitoring Costs (nine to 14 percent), Site Retention Costs (nine to 16 percent), and Central Laboratory Costs (four to 12 percent).

Price And Volume August 8, 2020 To Sept 11, 2020

Date	Open	High	Low	Close	VWAP	Volume	% Chg	$ Chg	Trade Val	# Trades
2020-09-11	0.27	0.27	0.26	0.265	0.2639	565.14k	1.92%	0.01	149,165.80	132
2020-09-10	0.26	0.27	0.25	0.26	0.2599	983.15k	0.00%	0.00	255,498.27	200
2020-09-09	0.265	0.265	0.255	0.26	0.2579	519.62k	0.00%	0.00	134,019.83	158
2020-09-08	0.265	0.265	0.25	0.26	0.2592	1.76m	-5.46%	-0.02	455,583.08	364
2020-09-04	0.265	0.275	0.26	0.275	0.2685	1.01m	3.77%	0.01	271,033.88	212
2020-09-03	0.275	0.28	0.265	0.265	0.2694	2.01m	-3.64%	-0.01	541,450.87	306
2020-09-02	0.29	0.29	0.27	0.275	0.2774	1.60m	-1.79%	-0.01	442,627.67	356
2020-09-01	0.305	0.31	0.275	0.28	0.2871	2.08m	-6.67%	-0.02	597,683.75	420
2020-08-31	0.29	0.32	0.285	0.30	0.2973	3.39m	7.14%	0.02	1,007,246.71	689
2020-08-28	0.265	0.28	0.26	0.28	0.2682	1.31m	7.69%	0.02	350,375.96	283
2020-08-27	0.27	0.27	0.255	0.26	0.2616	1.40m	-1.89%	-0.01	365,919.86	352
2020-08-26	0.30	0.30	0.26	0.265	0.2746	3.19m	0.00%	0.00	876,352.99	566
2020-08-25	0.275	0.275	0.25	0.265	0.2614	1.85m	0.00%	0.00	483,791.26	427
2020-08-24	0.28	0.29	0.26	0.265	0.2689	2.61m	-5.36%	-0.02	701,414.47	499
2020-08-21	0.285	0.29	0.275	0.28	0.2824	1.99m	0.00%	0.00	562,301.44	362
2020-08-20	0.31	0.31	0.28	0.28	0.2889	2.41m	-9.68%	-0.03	696,500.03	545
2020-08-19	0.27	0.345	0.27	0.31	0.3129	8.32m	10.71%	0.03	2,603,376.36	1,309
2020-08-18	0.305	0.305	0.27	0.28	0.2841	2.98m	-5.09%	-0.02	845,367.39	526
2020-08-17	0.30	0.32	0.29	0.295	0.3011	2.95m	-1.67%	-0.01	887,305.34	602
2020-08-14	0.295	0.345	0.29	0.30	0.3136	6.92m	7.14%	0.02	2,171,450.77	1,263

[1ottrunner]

TechG at what price did you short?  How many cents do you have to make to cover? NR this week takes us back into the 30's.  It may only be 10% but nothing wrong with that.

[Trippedstocks]

This isn't a normal phase 3... If it was the market cap would be close to a Billion. I feel you didn't consider that this isn't normal. How much does a company need to buy a drug, that is already manufactured, then send it home with a person? Does the trial need injection equipment? Nurses? Site rentals? Constant monitoring on machines? And it's not 30,000 people, it's 1000. It

[mrnormal]

Michael has already stated that he has 5-6 million in cash.More than enough to get it going. Funding isn't an issue.  News out anyday now. Let's GO!!

[CrazyProphet]

https://twitter.com/ScottWapnerCNBC/status/1305508680549511168?s=20

[1ottrunner]

Agreed Trippedstocks.  We may only need 3 sites to conduct the study within a month.  There are a lot of people with mild to moderate simptoms, 10's of thousands every day!

[TheIceMan3]

This GURU fellow must be a massive shorter....

[1ottrunner]

He must be a small short.  If he shorted a pile of shares he could likely cover. Regardless, none of the posts here sway the SP.  In fact I have a buy order in I can't fill, if I thought it would help I could bash but it simply doesn't work that way.

[1ottrunner]

Spoke too soon, managed to fill.  

[Trippedstocks]

looks like the volume is picking up....

[1ottrunner]

2 large sell orders just up, 139k and 259k @ .265